Ignite Creation Date:
2025-12-24 @ 6:39 PM
Ignite Modification Date:
2026-02-25 @ 11:01 PM
Study NCT ID:
NCT03071757
Status:
COMPLETED
Last Update Posted:
2022-04-28
First Post:
2017-03-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Sponsor:
AbbVie
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Solid Tumors Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Solid Tumors | View |
| None | Cancer | View |
| None | Metastatic Solid Tumors | View |
| None | Advanced Solid Tumors | View |
| None | Triple negative breast cancer (TNBC) | View |
| None | Ovarian cancer | View |
| None | Hepatocellular carcinoma (HCC) | View |
| None | Gastric cancer | View |
| None | Mesothelioma | View |
| None | Small cell lung cancer (SCLC) | View |
| None | Cholangiocarcinoma | View |
| None | Merkel cell carcinoma | View |
| None | Melanoma | View |
| None | Non-small cell lung cancer (NSCLC) | View |
| None | 2'-Deoxy-2'-[18F]Fluoro-9-β-DArabinofuranosylguanine (18F-AraG) | View |